Preparation and biodistribution of [18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography

被引:26
|
作者
Mou, Tiantian [1 ]
Jing, Huihui [1 ]
Yang, Wenjiang [1 ]
Fang, Wei [2 ,3 ]
Peng, Cheng [4 ]
Guo, Feng [2 ,3 ]
Zhang, Xianzhong [1 ]
Pang, Yan [1 ]
Ma, Yunchuan [4 ]
机构
[1] Beijing Normal Univ, Coll Chem, Minist Educ, Key Lab Radiopharmaceut, Beijing 100875, Peoples R China
[2] Chinese Acad Med Sci, Cardiovasc Inst, Dept Nucl Med, Beijing 100037, Peoples R China
[3] Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100037, Peoples R China
[4] Capital Med Univ, Xuan Wu Hosp, PET Ctr, Beijing 100053, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
Positron emission tomography; Myocardial perfusion imaging; F-18]FP2OP; Mitochondria complex I; FLOW TRACER; KINETIC-ANALYSIS; PET; COMPLEX; EXPRESSION;
D O I
10.1016/j.bmc.2009.12.022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myocardial extractions of pyridaben, a mitochondrial complex I (MC-I) inhibitor, is well correlated with blood flow. Based on the synthesis and characterization of pyridaben analogue 2-tert-butyl-5-[2-(2-[F-18]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([F-18]FP2OP), this study assessed its potential to be developed as myocardial perfusion imaging (MPI) agent. Methods: The tosylate labeling precursor 2-(2-(4-(tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)benzyloxy)ethoxy) ethyl ester (OTs-P2OP) and the nonradioactive 2-tert-butyl-5-[2-(2-[F-19]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([F-19]FP2OP) were synthesized and characterized by IR, H-1 NMR, C-13 NMR and MS analysis. By substituting tosyl of precursor OTs-P2OP with F-18, the radiolabeled complex [F-18]FP2OP was prepared and further evaluated for its in vitro physicochemical properties, in vivo biodistribution, the metabolic stability in mice, ex vivo autoradiography and cardiac PET/CT imaging. Results: Starting with [F-18]F Kryptofix 2.2.2./K2CO3 solution, the total reaction time for [F-18]FP2OP was about 100 min, with final high-performance liquid chromatography purification included. Typical decay-corrected radiochemical yield stayed at 41 +/- 5.3%, the radiochemical purity, 98% or more. Biodistribution in mice showed that the heart uptake of [F-18]FP2OP was 41.90 +/- 4.52% ID/g at 2 min post-injection time, when the ratio of heart/liver, heart/lung and heart/blood reached 6.83, 9.49 and 35.74, respectively. Lipophilic molecule was further produced by metabolized [F-18]FP2OP in blood and urine at 30 min. Ex vivo autoradiography demonstrates that [F-18]FP2OP may have high affinity with MC-I and that can be blocked by [F-19] FP2OP or rotenone (a known MC-I inhibitor). Cardiac PET images were obtained in a Chinese mini-swine at 5, 15, 30 and 60 min post-injection time with high quality. Conclusion: [F-18]FP2OP was synthesized with high radiochemical yield. The promising biological properties of [F-18]FP2OP suggest high potential as MPI agent for positron emission tomography in the future. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1312 / 1320
页数:9
相关论文
共 50 条
  • [1] Research Progress on 18F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography
    Mou, Tiantian
    Zhang, Xianzhong
    MOLECULES, 2017, 22 (04):
  • [2] [18F]-labeled 2-methoxyphenylpiperazine derivative as a potential brain positron emission tomography imaging agent
    Mou, Tiantian
    Yang, Wenjiang
    Peng, Cheng
    Zhang, Xianzhong
    Ma, Yunchuan
    APPLIED RADIATION AND ISOTOPES, 2009, 67 (11) : 2013 - 2018
  • [3] Steroids labeled with 18F for imaging tumors by positron emission tomography
    Katzenellenbogen, JA
    JOURNAL OF FLUORINE CHEMISTRY, 2001, 109 (01) : 49 - 54
  • [4] [18F]-FDopa positron emission tomography imaging in corticobasal syndrome
    El Ouartassi, Anais
    Giordana, Caroline
    Schiazza, Aurelie
    Chardin, David
    Darcourt, Jacques
    BRAIN IMAGING AND BEHAVIOR, 2023, 17 (06) : 619 - 627
  • [5] Biodistribution and stability studies of [18F]Fluoroethylrhodamine B, a potential PET myocardial perfusion agent
    Gottumukkala, Vijay
    Heinrich, Tobias K.
    Baker, Amanda
    Dunning, Patricia
    Fahey, Frederic H.
    Treves, S. Ted
    Packard, Alan B.
    NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (03) : 365 - 370
  • [6] A Welcomed New Myocardial Perfusion Imaging Agent for Positron Emission Tomography
    Beller, George A.
    Watson, Denny D.
    CIRCULATION, 2009, 119 (17) : 2299 - 2301
  • [7] Automated Synthesis of [18F]Fluoromethylcholine for Positron-Emission Tomography Imaging
    Fedorova, O. S.
    Vaitekhovich, F. P.
    Krasikova, R. N.
    PHARMACEUTICAL CHEMISTRY JOURNAL, 2018, 52 (08) : 730 - 734
  • [8] Positron emission tomography imaging of cell death with [18F]FPDuramycin
    Shaobo Yao
    Kongzhen Hu
    Ganghua Tang
    Xiang Liang
    Kan Du
    Dahong Nie
    Shende Jiang
    Linquan Zang
    Apoptosis, 2014, 19 : 841 - 850
  • [9] [18F]-FDopa positron emission tomography imaging in corticobasal syndrome
    Anaïs El Ouartassi
    Caroline Giordana
    Aurélie Schiazza
    David Chardin
    Jacques Darcourt
    Brain Imaging and Behavior, 2023, 17 : 619 - 627
  • [10] Positron emission tomography imaging of cell death with [18F]FPDuramycin
    Yao, Shaobo
    Hu, Kongzhen
    Tang, Ganghua
    Liang, Xiang
    Du, Kan
    Nie, Dahong
    Jiang, Shende
    Zang, Linquan
    APOPTOSIS, 2014, 19 (05) : 841 - 850